Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AxoSim touts results of nerve-on-a-chip study

July 9, 2019 By Nancy Crotti

AxoSimA new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders.

The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. These include robust axonal outgrowth, myelination of human stem cell-derived neurons by primary human Schwann cells, and evaluation of nerve conduction velocity, according to the New Orleans-based company.

The clinically relevant electrophysiological and histological metrics generated by Nerve-on-a-Chip can help elucidate how new drugs work and uncover the basic mechanisms driving nerve pathologies, such as toxicity, demyelination and other neurodegenerative conditions, according to the study, published in Nature Scientific Reports. The authors conclude that this human peripheral nerve model could accelerate human disease modeling, drug discovery and toxicity screening.

Michael J. Moore, professor of biomedical engineering and head of the neural microengineering laboratory at Tulane University, is a co-author of the new study and an inventor of the Nerve-on-a-Chip technology.

“Development of organ-on-a-chip systems for neuroscience applications has lagged. Yet there is great need for tools to accelerate the slow pace of new drug R&D for neurological disorders,” Moore said in a news release. “We developed the Nerve-on-a-Chip technology to give researchers and drug developers a biomimetic model that would provide human data much earlier in the process, thereby saving time and money and allowing researchers to focus on candidates with greater potential. This study confirms the success of our work with our collaborators at AxoSim in creating a powerful tool for human neurology translational and clinical research.”

“We believe that our Nerve-on-a-Chip platform is the first fully functional biomimetic microphysiological model of myelinated human peripheral nerves,” added AxoSim CEO Lowry Curley.  “Myelination is critical for proper neuronal functioning and impaired myelination is implicated in many neurological diseases.”

AxoSim is working with a number of major pharmaceutical and biotechnology partners to conduct studies using the platform, according to Curley.  The company raised $1.1 million in a round of equity financing, according to SEC filings posted in March.

Filed Under: Featured, Neurological, Research & Development, Stem Cells Tagged With: AxoSim

IN CASE YOU MISSED IT

  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • Medicina recalls IV Luer Slip syringes
  • Eitan Group signs service agreement with Integrated Medical Systems
  • Beta Bionics’ bionic pancreas wins breakthrough status from FDA
  • FDA details framework for abbreviated 510(k) medical device review pathway
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS